3 months to expiry Ghana · FDA Ghana

PHLEBODIA

DIOSMIN

FDA/SD.233-060640 TABLETS 600MG cardiovascular system INN generic

What it does

Diosmin is a natural substance that helps improve blood flow and support vein health.

Commonly used for: venous insufficiency (poor blood flow in the veins), hemorrhoids, varicose veins

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
FDA/SD.233-060640
Registration date
2023-06-19
Expiry date
2026-09-01
Status
3 months to expiry
Active ingredient
DIOSMIN
Dosage form
TABLETS
Strength
600MG
Pack size
-
Therapeutic class
-
ATC class (WHO)
C05CA - Bioflavonoids
RxNorm RxCUI
3489
Manufacturer / MAH
Innothera Chouzy
Country of origin
-
Manufacturer location
1 Rue René Chantereau, 41150 Valloire-sur-Cisse, France

Source: Food and Drugs Authority · fetched 2026-04-18 08:32:59 · updated 2026-09-01 04:00:32

Disclaimer: This information is sourced from Food and Drugs Authority (Ghana). Always consult a qualified healthcare professional before using any medication.

About this medicine

Diosmin is a natural substance that helps improve blood flow and support vein health.

What it treats

  • venous insufficiency (poor blood flow in the veins)
  • hemorrhoids
  • varicose veins

How it works

Diosmin strengthens the walls of blood vessels and reduces inflammation, helping to improve circulation.

Who it's for

Diosmin is for adults experiencing issues related to poor vein health, such as swelling, discomfort, or hemorrhoids.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: diosmin

BNF-referenced

Diosmin is a venoactive drug primarily used to support venous health and improve microcirculation. It is often indicated for conditions such as chronic venous insufficiency and hemorrhoids. Diosmin is believed to enhance venous tone and elasticity while reducing symptoms associated with venous disorders. It also possesses antioxidant properties, contributing to its overall beneficial effects on vascular health.

Indications

  • Chronic venous insufficiency
  • Hemorrhoids
  • Leg edema
  • Varicose veins

Dosage

Children: Refer to the BNF for Children for specific dosing information.

Adults: Refer to the BNF for specific dosing information.

Mechanism of action

Diosmin helps to maintain circulatory system structure and function, particularly vein strength and competence. Although the molecular mechanism of action is not fully established, diosmin is suggested to bind to the aryl hydrocarbon receptor, although the clinical relevance to vascular function remains unclear. It has been observed to influence the metabolism of noradrenaline in varicose veins, potentially benefiting vascular health.

Pharmacodynamics

Diosmin supports circulatory health through multiple mechanisms, including improving lymphatic drainage, enhancing microcirculation, and increasing venous tone and elasticity. It has shown to reduce oxidative stress by scavenging free radicals and lowering levels of inflammatory markers such as TNF alpha and IL-6. Clinical studies have demonstrated a reduction in edema and leg circumference in patients with chronic venous conditions after diosmin therapy.

Pharmacokinetics

Diosmin is well-absorbed from the gastrointestinal tract and undergoes extensive metabolism, primarily in the liver. The elimination half-life and specific metabolic pathways have not been extensively detailed, but it is known to be excreted in urine. The pharmacokinetic parameters may vary based on individual patient factors.

Adverse effects

  • Gastrointestinal discomfort
  • Nausea
  • Diarrhea
  • Headache
  • Allergic reactions

Precautions

  • Use with caution in patients with hypersensitivity to diosmin or any of its components.
  • Consult a healthcare provider before use in patients with underlying health conditions.

Pregnancy

The safety of diosmin in pregnancy has not been established. Use only if clearly needed and after assessing risks and benefits.

Breast-feeding

It is unknown whether diosmin is excreted in human milk. Caution is advised when administering to nursing mothers.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

  • Diosmin 500 mg tablets
  • Diosmin 1000 mg tablets

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

Molecular reference: diosmin

PubChem CID 5281613

Molecular formula: C28H32O15

Mechanism of action

Diosmin helps to maintain circulatory system structure and function, particularly vein strength and competence. The molecular mechanism of action of diosmin has not been established. Several resources indicate that diosmin binds to the aryl hydrocarbon receptor, however clinical relevance to vascular function is unknown. One study demonstrates that oral diosmin exerts effects on the in vitro metabolism of noradrenaline by varicose veins, potentially benefitting vascular health.

Pharmacodynamics

Diosmin is a venoactive drug supporting circulatory health through various actions on blood vessels; it supports lymphatic drainage and improves microcirculation while increasing venous tone and elasticity. For these reasons, diosmin is frequently taken by individuals with chronic venous disease to support vascular health and has been demonstrated to improve quality of life. In addition to the above effects, diosmin exerts antioxidant activity and scavenges oxygen free radicals, reducing levels of oxidative stress normally detected through biomarkers such as prostaglandins isoprostane precursors. In one clinical study, mean content of TNF alpha, VEGF-C, VEGF-A IL-6, in addition to FGF2 were decreased by after the therapy with diosmin; findings were statistically significant. Additionally, a decrease in edema and mean leg circumference of patients taking diosmin for three months was observed in a clinical study. Diosmin has been demonstrated to enhance the metabolism of glucose in diabetic disorders.

Source: PubChem (NCBI) · pathways from PathBank, Reactome, WikiPathways & PharmGKB.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.